Advances in the Diagnosis and Treatment of IBS-D: An Update for the Primary Care Setting

Engage with the faculty expert panel as they review strategies for managing IBS-D. Topics include:

  • Understanding the multifactorial pathophysiology of IBS
  • Establishing the diagnosis of IBS-D with Rome IV criteria
  • Selecting evidence-based, approved pharmacologic interventions for patients with IBS-D

This symposium is neither supported, sponsored, nor endorsed by the AAPA.

CCO members can quickly sign up now using the ‘Register’ button on the Event Details page. If you aren't a CCO member, email or call 1-855-224-2241 and we will register you. Meeting is complimentary.


6:00 AM - 6:30 AM Registration and Breakfast
6:30 AM - 6:40 AM Overview of IBS
6:40 AM - 6:55 AM Pathophysiology and Diagnosis

  • Multifactorial pathophysiology of IBS
  • Alarm features
  • Making a diagnosis of IBS-D based on Rome criteria

6:55 AM - 7:15 AM Treatment Considerations for IBS-D

  • Nonpharmacologic and over-the-counter pharmacologic interventions
  • Efficacy and safety of evidence-based treatments

7:15 AM - 7:30 AM Question and Answer Session


Date / Time
Event Details


Brooks D. Cash, MD

Visiting Professor of Medicine
Department of Medicine
McGovern Medical School
Department of Gastroenterology, Hepatology, and Nutrition
University of Texas Health Science Center at Houston/Memorial Hermann Hospital
Houston, Texas

Ashley Peace, Other

Physician Assistant
Division of Gastroenterology
University of South Alabama
Mobile, Alabama

The goal of this activity is to improve PAs’ competence in applying patient-focused strategies to communicate with patients about sensitive GI concerns, diagnosing IBS-D based on Rome criteria, and developing evidence-based treatment regimens for patients who have not responded to conventional therapies for IBS-D.

Target Audience
This program is intended for PAs and other healthcare providers who care for patients with IBS.

Learning Objectives

  • Apply Rome IV criteria in the diagnosis of IBS-D in patients with no warning signs or symptoms for other GI diseases with overlapping symptoms
  • Consider evidence-based therapies for patients with IBS-D who have not responded to dietary and over-the-counter pharmacologic interventions
  • Determine the appropriate dosage and regimen for evidence-based pharmacologic interventions for IBS-D


Physician Continuing Medical Education

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the American Gastroenterological Association and Clinical Care Options, LLC. American Gastroenterological Association is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

American Gastroenterological Association designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

In accordance with the ACCME’s Standards for Commercial Support of Continuing Medical Education, all faculty and planning partners must disclose any financial relationship(s) or other relationship(s) held within the past 12 months. The AGA Institute implements a mechanism to identify and resolve all conflicts of interest prior to delivering the educational activity to learners.

Physician Assistant Continuing Medical Education

This activity has been reviewed and is approved for a maximum of 1.00 AAPA Category 1 CME credit by the AAPA Review Panel. PAs should claim only those credits actually spent participating in the CME activity.

This activity was planned in accordance with AAPA CME Standards for Live Programs and for Commercial Support of Live Programs.